Cannabidiol Gel Achieves Top Line Results in Treatment of Fragile X Syndrome

The investigational cannabidiol (CBD) gel ZYN002 achieved positive top line results in a phase 2 study for the treatment of Fragile X syndrome.
ZYN002 is a permeation-enhanced gel designed to provide controlled drug delivery transdermally once or twice per day, according to a press release.
Included in the open label exploratory phase 2 FAB-C clinical trial were 20 patients aged 6 to 17 years with confirmed Fragile X. According to the release, ZYN002 was added on to other medications being administered.
The first 6 weeks of the study were designed to titrate dosing in participants. Dosing was initiated at 50 mg per day and could be increased to 250 mg daily. Week 7 through 12 was a maintenance period, in which patients were treated with the dose established at 6 weeks.
Once the study was completed, patients had the option to enter an open label extension

... read more at: